Literature DB >> 19455589

Diverse genomic integration of a lentiviral vector developed for the treatment of Wiskott-Aldrich syndrome.

Julie Mantovani1, Sabine Charrier, Ralph Eckenberg, William Saurin, Olivier Danos, Javier Perea, Anne Galy.   

Abstract

BACKGROUND: The genomic integration of a lentiviral vector developed for the treatment of Wiskott-Aldrich syndrome (WAS) was assessed by localizing the vector insertion sites (IS) in a murine model of gene therapy for the disease.
METHODS: Transduced hematopoietic progenitor cells were transplanted into mice or cultured in vitro. The IS were determined in the genomic DNA from blood, the bone marrow of the animals and from cultured cells.
RESULTS: Sequencing vector-genomic DNA junctions yielded more than 150 IS of which 50-70% were located in transcription units. To obtain additional sequences from the population of cultured cells, we used a vector-tag concatenation technique providing 190 additional IS. Altogether, the profiles confirmed the bias for integration in transcription units. The vector did not congregate as hotspots and did not appear to target specific categories of genes. The diversity of the IS reflected the initial marking of a polyclonal population of cells. However, relatively few vector IS were found in vivo because only 30-40 unique IS were identified in each mouse using this approach. Although four to ten IS were shared by the blood and bone marrow, no common IS was found between mice or between any mouse and the cultured cells.
CONCLUSIONS: Taken as a whole, the pattern of genomic insertion of the WAS lentiviral vector was diverse and similar to that previously described for other HIV-1-derived lentiviral vectors. Testing cells destined for transplantation is unlikely to predict specific IS to be selected in vivo.

Entities:  

Mesh:

Year:  2009        PMID: 19455589     DOI: 10.1002/jgm.1346

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  6 in total

1.  Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome.

Authors:  Toru Uchiyama; Marsilio Adriani; G Jayashree Jagadeesh; Adam Paine; Fabio Candotti
Journal:  Mol Ther       Date:  2012-01-03       Impact factor: 11.454

Review 2.  Lentiviral vectors in gene therapy: their current status and future potential.

Authors:  David Escors; Karine Breckpot
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-02-09       Impact factor: 4.291

3.  Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat β-thalassemia.

Authors:  Keshet Ronen; Olivier Negre; Shannah Roth; Charlotte Colomb; Nirav Malani; Maria Denaro; Troy Brady; Floriane Fusil; Beatrix Gillet-Legrand; Kathleen Hehir; Yves Beuzard; Philippe Leboulch; Julian D Down; Emmanuel Payen; Frederic D Bushman
Journal:  Mol Ther       Date:  2011-03-08       Impact factor: 11.454

Review 4.  Sites of retroviral DNA integration: From basic research to clinical applications.

Authors:  Erik Serrao; Alan N Engelman
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-10-28       Impact factor: 8.250

5.  Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome.

Authors:  Samantha Scaramuzza; Luca Biasco; Anna Ripamonti; Maria C Castiello; Mariana Loperfido; Elena Draghici; Raisa J Hernandez; Fabrizio Benedicenti; Marina Radrizzani; Monica Salomoni; Marco Ranzani; Cynthia C Bartholomae; Elisa Vicenzi; Andrea Finocchi; Robbert Bredius; Marita Bosticardo; Manfred Schmidt; Christof von Kalle; Eugenio Montini; Alessandra Biffi; Maria G Roncarolo; Luigi Naldini; Anna Villa; Alessandro Aiuti
Journal:  Mol Ther       Date:  2012-02-28       Impact factor: 11.454

6.  Quantification of lentiviral vector copy numbers in individual hematopoietic colony-forming cells shows vector dose-dependent effects on the frequency and level of transduction.

Authors:  S Charrier; M Ferrand; M Zerbato; G Précigout; A Viornery; S Bucher-Laurent; S Benkhelifa-Ziyyat; O W Merten; J Perea; A Galy
Journal:  Gene Ther       Date:  2010-12-16       Impact factor: 5.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.